Hercules Capital, Inc.

NYSE:HTGC Voorraadrapport

Marktkapitalisatie: US$3.2b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Hercules Capital Beheer

Beheer criteriumcontroles 2/4

De CEO Hercules Capital's is Scott Bluestein, benoemd in Apr2014, heeft een ambtstermijn van 10.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.89M, bestaande uit 7.3% salaris en 92.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.35% van de aandelen van het bedrijf, ter waarde $ 42.45M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 4.3 jaar.

Belangrijke informatie

Scott Bluestein

Algemeen directeur

US$8.9m

Totale compensatie

Percentage CEO-salaris7.3%
Dienstverband CEO10.5yrs
Eigendom CEO1.3%
Management gemiddelde ambtstermijn5.8yrs
Gemiddelde ambtstermijn bestuur4.3yrs

Recente managementupdates

Recent updates

Hercules Capital: How Good Is This 10% Yield?

Oct 15

Hercules Capital: The Yield And Underlying Value Remain Attractive

Sep 13

Hercules Capital: This 10% Yield Is On Sale (Rating Upgrade)

Aug 26

Hercules Capital BDC: 10% Yield, Record Earnings

Aug 09

Hercules Capital (NYSE:HTGC) Is Paying Out A Dividend Of $0.48

Aug 02
Hercules Capital (NYSE:HTGC) Is Paying Out A Dividend Of $0.48

Hercules Capital: Recent Improvements But Currently Very Expensive

Jul 22

Hercules Capital: 2 Possible Outcomes (Rating Downgrade)

Jul 08

Hercules Capital: A Solid Dividend Stock But Valuation Concerns Are Valid

Jun 25

Hercules Capital: A Premium Company, But Better To Wait Until Interest Rates Decrease

Jun 07

Hercules Capital: Solid 10% Yield, But Sky-High Valuation

May 10

Hercules Capital: VC-Focused Name With Less Risk And Better Return Prospects Than Average BDC

May 04

Hercules Capital: Winning Option In The Financial Services Space

Apr 24

There Is A Reason Hercules Capital, Inc.'s (NYSE:HTGC) Price Is Undemanding

Apr 22
There Is A Reason Hercules Capital, Inc.'s (NYSE:HTGC) Price Is Undemanding

Hercules Capital: Record Year In 2023, 10% Yield

Mar 29

Unlocking Hercules Capital's Income Potential: A Fresh Look At Dividend Timing Strategies

Feb 23

Results: Hercules Capital, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Feb 18
Results: Hercules Capital, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Hercules Capital: Still Resilient With Solid Prospects Despite The VC Focus

Feb 17

Hercules Capital: A Different Type Of VC-Focused BDC

Jan 16

Hercules Capital Poised For Potential Market Surge In 2024

Dec 24

Lacklustre Performance Is Driving Hercules Capital, Inc.'s (NYSE:HTGC) Low P/E

Dec 18
Lacklustre Performance Is Driving Hercules Capital, Inc.'s (NYSE:HTGC) Low P/E

10%-Yielding Hercules Capital: Better Ingredients, Better Outcomes

Dec 15

Main Street Capital Vs. Hercules Capital: Why Choose?

Nov 22

Hercules Capital: 10% Yield, My Largest BDC Position

Nov 13

10%-Yielding Hercules Capital Is A BDC Superstar

Oct 10

Hercules Capital: Venture Capital Financier Offering High Yield And Robust Balance Sheet

Sep 17

Hercules Capital: 10% Yield, Strong Coverage, Low Leverage

Sep 09

Let's Build A Bond Portfolio Together: Hercules Capital Bonds 2026 7.10%

Aug 15

Hercules Capital: Fatter Yield, Surging Stock Price

Aug 05

Hercules Capital: The Tide Is Turning - Buy While It's Cheap (Rating Upgrade)

Jun 28

Hercules Capital raises dividend by 8.3% to $0.39/share, supplemental cash distribution of $0.08

Feb 14

Hercules Capital: 2 Top Reasons To Buy This 10.1%-Yielding BDC

Jan 25

Should You Buy Hercules Capital Before Or After Its Ex-Dividend Date?

Jan 11

Hercules Capital: Bear Market Rally Fizzling Out

Dec 08

Oak Street Health secures $300M in financing

Nov 16

Hercules Capital: Double Your Cash Flow With This 10%+ Dividend

Nov 07

Analyse CEO-vergoeding

Hoe is Scott Bluestein's beloning veranderd ten opzichte van Hercules Capital's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

US$278m

Mar 31 2024n/an/a

US$331m

Dec 31 2023US$9mUS$650k

US$334m

Sep 30 2023n/an/a

US$277m

Jun 30 2023n/an/a

US$302m

Mar 31 2023n/an/a

US$197m

Dec 31 2022US$7mUS$650k

US$100m

Sep 30 2022n/an/a

US$42m

Jun 30 2022n/an/a

US$12m

Mar 31 2022n/an/a

US$105m

Dec 31 2021US$6mUS$650k

US$172m

Sep 30 2021n/an/a

US$319m

Jun 30 2021n/an/a

US$339m

Mar 31 2021n/an/a

US$318m

Dec 31 2020US$7mUS$650k

US$226m

Sep 30 2020n/an/a

US$120m

Jun 30 2020n/an/a

US$96m

Mar 31 2020n/an/a

US$83m

Dec 31 2019US$8mUS$594k

US$173m

Sep 30 2019n/an/a

US$111m

Jun 30 2019n/an/a

US$128m

Mar 31 2019n/an/a

US$132m

Dec 31 2018US$11mUS$515k

US$76m

Sep 30 2018n/an/a

US$111m

Jun 30 2018n/an/a

US$109m

Mar 31 2018n/an/a

US$90m

Dec 31 2017US$3mUS$500k

US$78m

Compensatie versus markt: De totale vergoeding ($USD 8.89M ) Scott } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).

Compensatie versus inkomsten: De beloning van Scott is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.


CEO

Scott Bluestein (46 yo)

10.5yrs

Tenure

US$8,891,994

Compensatie

Mr. Scott Bluestein is Miscellaneous of UBS Securities LLC. He is Chief Executive Officer, Chief Investment Officer, President and Director of Hercules Capital, Inc. He joined the Hercules Capital, Inc. in...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Scott Bluestein
CEO, Chief Investment Officer10.5yrsUS$8.89m1.34%
$ 43.2m
Seth Meyer
CFO & Chief Accounting Officer5.6yrsUS$3.04m0.21%
$ 6.7m
Christian Follmann
Chief Operating Officer8.8yrsUS$1.21m0.059%
$ 1.9m
Kiersten Botelho
Corporate Secretary2.8yrsUS$1.08m0.029%
$ 948.3k
Steve Kuo
Senior MD & Group Head of Technology5.8yrsgeen gegevensgeen gegevens
Michael Hara
Managing Director of Investor Relations & Corporate Communicationsno datageen gegevensgeen gegevens
Kate Kinlin
VP of Human Resources2.5yrsgeen gegevensgeen gegevens
Roy Liu
Managing Director20.5yrsgeen gegevensgeen gegevens
R. Jadot
Senior MD & Group Head of Life Sciences5.4yrsgeen gegevensgeen gegevens
Michael Bowden
Managing Director of Portfolio Management5.8yrsgeen gegevensgeen gegevens
Janice Bourque
Managing Director14.5yrsgeen gegevensgeen gegevens
Lesya Kulchenko
Managing Director5.8yrsgeen gegevensgeen gegevens

5.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HTGC is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Scott Bluestein
CEO, Chief Investment Officer5.3yrsUS$8.89m1.34%
$ 43.2m
Gayle Crowell
Independent Director5.7yrsUS$215.00k0.037%
$ 1.2m
Robert Badavas
Chairman of the Board & Lead Independent Director18.6yrsUS$310.00k0.070%
$ 2.3m
Pam Randhawa
Independent Director2.9yrsUS$250.00k0.010%
$ 322.5k
Nikos Theodosopoulos
Independent Director1.1yrsUS$39.99k0.0035%
$ 113.4k
Thomas Fallon
Independent Director10.3yrsUS$205.00k0.062%
$ 2.0m
Wade Loo
Independent Director3.3yrsUS$215.00k0.017%
$ 533.8k
DeAnne Aguirre
Independent Board Directors2.3yrsUS$145.00k0.0086%
$ 277.2k

4.3yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HTGC wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).